39,549 research outputs found
Erratum to: Effect of moderate red wine intake on cardiac prognosis after recent acute myocardial infarction of subjects with Type 2 diabetes mellitus (Diabetic Medicine, (2006), 23, 9, (974-981), 10.1111/j.1464-5491.2006.01886.x)
No full textIn an article by Marfella et al, the author name C. Saron is incorrect and should be listed as C. Sardu. Therefore the correct author list is: R. Marfella, F. Cacciapuoti, M. Siniscalchi, F. C. Sasso, F. Marchese, F. Cinone, E. Musacchio, M. A. Marfella, L. Ruggiero, G. Chiorazzo, D. Liberti, G. Chiorazzo, G. F. Nicoletti, C. Sardu, F. D'Andrea, C. Ammendola, M. Verza and L. Coppola.In an article by Marfella et al, the author name C. Saron is incorrect and should be listed as C. Sardu. Therefore the correct author list is: R. Marfella, F. Cacciapuoti, M. Siniscalchi, F. C. Sasso, F. Marchese, F. Cinone, E. Musacchio, M. A. Marfella, L. Ruggiero, G. Chiorazzo, D. Liberti, G. Chiorazzo, G. F. Nicoletti, C. Sardu, F. D'Andrea, C. Ammendola, M. Verza and L. Coppola
TGF-beta 1 stimulation of cell locomotion utilizes the hyaluronan receptor RHAMM and hyaluronan.
No full textTGF-beta is a potent stimulator of motility in a variety of cell types. It has recently been shown that hyaluronan (HA) can directly promote locomotion of cells through interaction with the HA receptor RHAMM. We have investigated the role of RHAMM and HA in TGF-beta-stimulated locomotion and show that TGF-beta triggers the transcription, synthesis and membrane expression of the RHAMM receptor and the secretion of HA coincident with the induction of the locomotory response. This was demonstrated by both incubating cells with exogenous TGF-beta1 and by stimulating the production of bioactive TGF-beta1 in tumor cells transfected with TGF-beta1 under the control of the metallothionein promoter. TGF-beta1-induced locomotion was suppressed by antibodies that prevented HA/RHAMM interaction, using polyclonal antibodies to either RHAMM fusion protein or RHAMM peptides, or mAbs to purified RHAMM. Peptides corresponding to the HA-binding motif of RHAMM also suppressed TGF-beta1-induced increases in motility rate. Spontaneous locomotion of fibrosarcoma cells was blocked by neutralizing secreted TGF-beta with panspecific TGF-beta antibodies and by inhibition of TGF-beta1 secretion with antisense oligonucleotides. Polyclonal anti-RHAMM fusion protein antibodies and peptide from the RHAMM HA-binding motif also suppressed the spontaneous motility rate of fibrosarcoma cells. These data suggest that fibrosarcoma cell locomotion requires TGF-beta, and the pathway by which TGF-beta stimulates locomotion uses the HA receptor RHAMM and HA.PT: J; CR: ALLEN JB, 1990, J EXP MED, V171, P231 ANZANO MA, 1985, MOL CELL BIOL, V5, P242 BARNARD JA, 1990, BIOCHIM BIOPHYS ACTA, V1032, P79 BASSOLS A, 1988, J BIOL CHEM, V263, P3039 BRAY BA, 1991, AM REV RESPIR DIS, V143, P284 CHAN BM, 1992, CELL, V68, P1051 CHEN JK, 1987, P NATL ACAD SCI USA, V84, P5287 CULTY M, 1990, J CELL BIOL 1, V111, P2765 DALAL BI, 1993, AM J PATHOL, V143, P381 DANIELPOUR D, 1989, J CELL PHYSIOL, V138, P79 DELPECH B, 1981, J NEUROCHEM, V36, P855 DERYNCK R, 1987, CANCER RES, V47, P707 DOEGE K, 1987, J BIOL CHEM, V262, P17757 FASSEN AE, 1992, J CELL BIOL, V116, P521 FAVA RA, 1991, J EXP MED, V173, P1121 GOETINCK PF, 1987, J CELL BIOL, V105, P2403 GOUGH NM, 1988, ANAL BIOCHEM, V173, P93 HARDWICK C, 1992, J CELL BIOL, V117, P1343 HEINE UI, 1987, J CELL BIOL, V105, P286 HEINO J, 1989, J BIOL CHEM, V264, P380 HELDIN P, 1989, BIOCHEM J, V258, P919 HOOK M, 1984, ANNU REV BIOCHEM, V53, P847 HURTA RAR, 1991, J BIOL CHEM, V266, P24097 HYNES RO, 1992, CELL, V69, P11 KAHARI VM, 1991, J BIOL CHEM, V266, P10608 KHALIL N, 1989, J EXP MED, V170, P727 KHALIL N, 1991, CIBA F SYMP, V157, P194 KIMATA K, 1983, CANCER RES, V43, P1347 KLEINSOYER C, 1989, ARTERIOSCLEROSIS, V9, P147 KRUSIUS T, 1987, J BIOL CHEM, V262, P13120 LAEMMLI UK, 1970, NATURE, V227, P680 LIOTTA LA, 1988, CANCER SURV, V7, P631 MADRI JA, 1988, J CELL BIOL, V106, P1375 MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597 MCCARTHY JB, 1992, IN PRESS CRC CRIT RE MCCLARTY GA, 1987, BIOCHEM BIOPH RES CO, V145, P1276 MOORADIAN DL, 1992, J NATL CANCER I, V84, P523 NEAME PJ, 1986, J BIOL CHEM, V261, P3519 NETTELBLADT O, 1989, AM REV RESPIR DIS, V139, P759 NUGENT MA, 1992, J BIOL CHEM, V267, P21256 PARTIN AW, 1988, CANCER RES, V48, P6050 PARTIN AW, 1989, P NATL ACAD SCI USA, V86, P1254 PERIDES G, 1989, J BIOL CHEM, V264, P5981 PEROTTI D, 1991, CANCER RES, V51, P5491 PIERCE GF, 1989, P NATL ACAD SCI USA, V86, P2229 POSTLETHWAITE AE, 1987, J EXP MED, V165, P251 REIBMAN J, 1991, P NATL ACAD SCI USA, V88, P6805 ROBERTS AB, 1990, HDB EXPT PHARM, V95, P419 SAMUEL SK, 1992, EMBO J, V11, P1599 SATO Y, 1988, J CELL BIOL, V107, P1199 SCHOR SL, 1989, IN VITRO CELL DEV B, V25, P737 SCHWARZ LC, 1990, GROWTH FACTORS, V3, P115 STAMENKOVIC I, 1991, EMBO J, V10, P343 STOKER M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P81 THOMAS L, 1992, J CELL BIOL, V118, P971 TOOLE BP, 1979, P NATL ACAD SCI USA, V76, P6299 TOOLE BP, 1989, CIBA F SYMP, V143, P138 TOOLE BP, 1990, CURR OPIN CELL BIOL, V2, P839 TURLEY EA, 1985, CANCER RES, V45, P5098 TURLEY EA, 1985, EXP CELL RES, V161, P17 TURLEY EA, 1987, BIOCHEMISTRY-US, V26, P2997 TURLEY EA, 1989, EXP CELL RES, V181, P340 TURLEY EA, 1991, ADV DRUG DELIVER REV, V7, P257 TURLEY EA, 1991, J CELL BIOL, V112, P1041 WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788 WELSH DR, 1991, P NATL ACAD SCI USA, V87, P7678 YAMADA KM, 1990, CANCER RES, V50, P4485 YAMAGUCHI Y, 1990, NATURE, V346, P281 YANG BH, 1993, J BIOL CHEM, V268, P8617; NR: 69; TC: 73; J9: J CELL BIOL; PG: 10; GA: ME817Source type: Electronic(1
Mitomycin C in highly myopic eyes - Author reply
No full textOphthalmology. 2005 Feb;112(2):208-18; discussion 219.
Mitomycin C modulation of corneal wound healing after photorefractive keratectomy in highly myopic eyes.
Gambato C, Ghirlando A, Moretto E, Busato F, Midena E.
SourceRefractive Surgery Service and Antimetabolite Therapy Research Unit, Department of Ophthalmology, University of Padova, Padova, Italy.
Abstract
PURPOSE: To evaluate the role of topical mitomycin C in corneal wound healing (CWH) after photorefractive keratectomy (PRK) in highly myopic eyes.
DESIGN: Prospective, double-masked, randomized clinical trial.
PARTICIPANTS: Seventy-two eyes of 36 patients affected by high (>7 diopters) myopia.
METHODS: In each patient, one eye was randomly assigned to PRK with intraoperative topical 0.02% mitomycin C application, and the fellow eye was treated with a placebo. Postoperatively, mitomycin C-treated eyes received artificial tears (3 times daily, tapered in 3 months), whereas the fellow eye was treated with fluorometholone sodium 2% and artificial tears (3 times daily, tapered in 3 months).
MAIN OUTCOME MEASURES: Uncorrected visual acuity (UCVA) and best-corrected visual acuity (BCVA), contrast sensitivity, manifest refraction, and biomicroscopy. Contrast sensitivity was determined using the Pelli-Robson chart. Corneal confocal microscopy documented CWH.
RESULTS: Mean follow-up was 18 months (range, 12-36). No side effects or toxic effects were documented. At 12-month follow-up examination, UCVAs (logarithm of the minimum angle of resolution) were 0.4+/-0.48 and 0.5+/-0.53 (P = .03) in mitomycin C-treated eyes and corticosteroid-treated eyes, respectively. At 1 year, corneal haze developed in 20% of corticosteroid-treated eyes, versus 0% of mitomycin C-treated eyes. At 12, 24, and 36 months, corneal confocal microscopy showed activated keratocytes and extracellular matrix significantly more evident in untreated eyes (Ps = 0.004, 0.024, and 0.046, respectively).
CONCLUSION: Topical intraoperative application of 0.02% mitomycin C can reduce haze formation in highly myopic eyes undergoing PRK.
Comment in
Ophthalmology. 2006 Feb;113(2):357; author reply 357-8
Six Overtures Composed by C. F. Abel. Adapted for the Harpsichord or Piano Forte : being Opera First / By the Author
No full textSIX OVERTURES COMPOSED BY C. F. ABEL. ADAPTED FOR THE HARPSICHORD OR PIANO FORTE : BEING OPERA FIRST / BY THE AUTHOR
Six Overtures Composed by C. F. Abel. Adapted for the Harpsichord or Piano Forte : being Opera First / By the Author (1)
Cover (1)
Titelseite (2)
Overture I. (3)
Overture II. (8)
Overture III. (12)
Overture IV. (16)
Overture V. (20)
Overture VI. (24
Lympha technique for primary and early secondary prevention of lymphedema following cancer treatment
No full textLYMPHA proved to be an effective preventive procedure that contributes in giving our oncological patients a good quality of life. In this presentation, the author will report indications, technical aspects and benefits of LYMPHA technique
A Relational Unsupervised Approach to Author Identification
No full textIn the last decades speaking and writing habits have changed.
Many works faced the author identification task by exploiting frequencybased
approaches, numeric techniques or writing style analysis. Following
the last approach we propose a technique for author identification
based on First-Order Logic. Specifically, we translate the complex data
represented by natural language text to complex (relational) patterns
that represent the writing style of an author. Then, we model an author
as the result of clustering the relational descriptions associated to the
sentences. The underlying idea is that such a model can express the typical
way in which an author composes the sentences in his writings. So,
if we can map such writing habits from the unknown-author model to
the known-author model, we can conclude that the author is the same.
Preliminary results are promising and the approach seems viable in real
contexts since it does not need a training phase and performs well also
with short texts
Evidence for the decay B0→J/ψω and measurement of the relative branching fractions of meson decays to J/ψη and J/ψη′
No full textFirst evidence of the B 0 → J / ψ ω decay is found and the B s 0 → J / ψ η and B s 0 → J / ψ η ′ decays are studied using a dataset corresponding to an integrated luminosity of 1.0 fb -1 collected by the LHCb experiment in proton-proton collisions at a centre-of-mass energy of sqrt(s) = 7 TeV. The branching fractions of these decays are measured relative to that of the B 0 → J / ψ ρ 0 decay:frac(B (B 0 → J / ψ ω), B (B 0 → J / ψ ρ 0)) = 0.89 ± 0.19 (stat) - 0.13 + 0.07 (syst),frac(B (B s 0 → J / ψ η), B (B 0 → J / ψ ρ 0)) = 14.0 ± 1.2 (stat) - 1.5 + 1.1 (syst) - 1.0 + 1.1 (frac(f d, f s)),frac(B (B s 0 → J / ψ η ′), B (B 0 → J / ψ ρ 0)) = 12.7 ± 1.1 (stat) - 1.3 + 0.5 (syst) - 0.9 + 1.0 (frac(f d, f s)), where the last uncertainty is due to the knowledge of f d / f s, the ratio of b-quark hadronization factors that accounts for the different production rate of B 0 and B s 0 mesons. The ratio of the branching fractions of B s 0 → J / ψ η ′ and B s 0 → J / ψ η decays is measured to befrac(B (B s 0 → J / ψ η ′), B (B s 0 → J / ψ η)) = 0.90 ± 0.09 (stat) - 0.02 + 0.06 (syst)
A 0.12mm<sup>2</sup> Wien-Bridge Temperature Sensor with 0.1°C (3σ) Inaccuracy from -40°C to 180°C
No full text Resistor-based temperature sensors can achieve much higher resolution and energy efficiency than conventional BJT-based sensors [1], but they typically occupy more area (> 0.25 mm 2 ) and have lower operating temperatures (le 125 {circ} {C}) [2]-[4]. This work describes a 0.12mm 2 resistor-based sensor that uses a Wien-bridge (WB) filter to achieve 0.1 {circ} {C} (3 sigma) inaccuracy from - 40 {circ} {C} to 180 {circ} {C}. Compared to a state-of-the-art WB sensor [4], it occupies 6 × less area and achieves comparable relative accuracy over a 76% wider operating range. Session 10.3 Green Open Access added to TU Delft Institutional Repository ‘You share, we take care!’ – Taverne project https://www.openaccess.nl/en/you-share-we-take-care Otherwise as indicated in the copyright section: the publisher is the copyright holder of this work and the author uses the Dutch legislation to make this work public.Electronic InstrumentationMicroelectronic
MITOMYCIN C MODULATION OF CORNEAL WOUND HEALING AFTER PHOTOREFRACTIVE KERATECTOMY IN HIGHLY MYOPIC EYES
No full textOphthalmology. 2005 Feb;112(2):208-18; discussion 219.
Mitomycin C modulation of corneal wound healing after photorefractive keratectomy in highly myopic eyes.
Gambato C, Ghirlando A, Moretto E, Busato F, Midena E.
SourceRefractive Surgery Service and Antimetabolite Therapy Research Unit, Department of Ophthalmology, University of Padova, Padova, Italy.
Abstract
PURPOSE: To evaluate the role of topical mitomycin C in corneal wound healing (CWH) after photorefractive keratectomy (PRK) in highly myopic eyes.
DESIGN: Prospective, double-masked, randomized clinical trial.
PARTICIPANTS: Seventy-two eyes of 36 patients affected by high (>7 diopters) myopia.
METHODS: In each patient, one eye was randomly assigned to PRK with intraoperative topical 0.02% mitomycin C application, and the fellow eye was treated with a placebo. Postoperatively, mitomycin C-treated eyes received artificial tears (3 times daily, tapered in 3 months), whereas the fellow eye was treated with fluorometholone sodium 2% and artificial tears (3 times daily, tapered in 3 months).
MAIN OUTCOME MEASURES: Uncorrected visual acuity (UCVA) and best-corrected visual acuity (BCVA), contrast sensitivity, manifest refraction, and biomicroscopy. Contrast sensitivity was determined using the Pelli-Robson chart. Corneal confocal microscopy documented CWH.
RESULTS: Mean follow-up was 18 months (range, 12-36). No side effects or toxic effects were documented. At 12-month follow-up examination, UCVAs (logarithm of the minimum angle of resolution) were 0.4+/-0.48 and 0.5+/-0.53 (P = .03) in mitomycin C-treated eyes and corticosteroid-treated eyes, respectively. At 1 year, corneal haze developed in 20% of corticosteroid-treated eyes, versus 0% of mitomycin C-treated eyes. At 12, 24, and 36 months, corneal confocal microscopy showed activated keratocytes and extracellular matrix significantly more evident in untreated eyes (Ps = 0.004, 0.024, and 0.046, respectively).
CONCLUSION: Topical intraoperative application of 0.02% mitomycin C can reduce haze formation in highly myopic eyes undergoing PRK.
Comment in
Ophthalmology. 2006 Feb;113(2):357; author reply 357-8.
PMID: 15691552 [PubMed - indexed for MEDLINE
APC/C and SCFcyclin F Constitute a Reciprocal Feedback Circuit Controlling S-Phase Entry
No full textSummaryThe anaphase promoting complex/cyclosome (APC/C) is an ubiquitin ligase and core component of the cell-cycle oscillator. During G1 phase, APC/C binds to its substrate receptor Cdh1 and APC/CCdh1 plays an important role in restricting S-phase entry and maintaining genome integrity. We describe a reciprocal feedback circuit between APC/C and a second ubiquitin ligase, the SCF (Skp1-Cul1-F box). We show that cyclin F, a cell-cycle-regulated substrate receptor (F-box protein) for the SCF, is targeted for degradation by APC/C. Furthermore, we establish that Cdh1 is itself a substrate of SCFcyclin F. Cyclin F loss impairs Cdh1 degradation and delays S-phase entry, and this delay is reversed by simultaneous removal of Cdh1. These data indicate that the coordinated, temporal ordering of cyclin F and Cdh1 degradation, organized in a double-negative feedback loop, represents a fundamental aspect of cell-cycle control. This mutual antagonism could be a feature of other oscillating systems
- …
